IDP Pharma

Executive Summary

IDP Pharma is a Barcelona-based pre-clinical biotech advancing a novel platform, Intrametics, designed to target and degrade intrinsically disordered proteins (IDPs). IDPs represent a large class of proteins that are historically considered 'undruggable' due to their lack of stable three-dimensional structures, making them difficult to target with conventional small molecules. The Intrametics platform aims to directly bind and degrade these proteins, potentially unlocking a new frontier in therapeutics for diseases where IDPs play a key role, such as cancer and neurodegenerative disorders. Founded in 2014, IDP Pharma has remained largely under the radar, with no disclosed funding or pipeline details. As a pre-clinical stage company, its core asset is the platform technology itself, which will need to demonstrate target engagement and efficacy in animal models before advancing to clinical trials. The company's success hinges on securing investment and establishing proof-of-concept for its approach. Given the high unmet need for IDP-targeted therapies, IDP Pharma's platform could be transformative if validated. However, the early stage and lack of public data make it a high-risk opportunity. Immediate focus will be on translating the platform into lead candidates and attracting partnerships or series funding to support IND-enabling studies.

Upcoming Catalysts (preview)

• Q2 2026Series A Funding Announcement30% success
• Q4 2026Lead Candidate Nomination from Intrametics Platform20% success
• Q1 2027In Vivo Proof-of-Concept Data Release25% success